GTBP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GT Biopharma Inc (GTBP) is not a strong buy for a beginner investor with a long-term strategy at this time. The technical indicators are bearish, and the stock shows a high probability of declining in the short to medium term. Additionally, the company's financial performance is weak, with no revenue and significant losses. While analysts maintain a Buy rating, the price target has been significantly lowered, and no immediate positive catalysts are present. Given the lack of strong trading signals and the absence of recent news or influential trading activity, it is best to hold off on investing in this stock.
The technical indicators are bearish. The MACD is below zero and negatively contracting, the RSI is neutral at 47.646, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels indicate limited upward momentum, with resistance at 0.446 and support at 0.363. The stock has a 70% chance of declining in the next day (-2.71%), week (-2.5%), and month (-12.18%).
It also plans to start a Phase 1 basket trial for GTB-5550 in mid-2026.
The stock also has a high probability of short-term decline.
In Q4 2025, the company reported no revenue, a net income of -$28.9M (up 665.48% YoY), and an EPS of -2.23 (up 33.53% YoY). Gross margin remains at 0%. The financials indicate ongoing losses with no revenue generation.
Analysts maintain a Buy rating but have significantly lowered the price target from $8 to $3, citing increased dilution and no immediate catalysts until 2026.
